VANCOUVER, British Columbia and MENLO PARK, Calif., July 27, 2015 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it has accepted subscriptions from institutional and accredited investors for a registered direct placement ("Placement") of 3.35 million shares of common stock and 3.35 million common stock purchase warrants for aggregate purchases of $2 million.
Each common share was purchased at a price of $0.60 per share and each common stock purchase warrant entitles the holder to purchase an additional share of the Company's common stock at a price of $0.75 per share for a period of five years.
Included in the subscriptions announced today are $1.3 million in purchases from existing DelMar Shareholders, including $157,000 from Directors and Officers of the Company.
"We are very pleased for the continued strong support from our existing shareholders as we continue to pursue our mission to benefit patients and create shareholder value by rapidly developing and commercializing anti-cancer therapies," said Jeffrey Bacha, DelMar's president & CEO.
DelMar will use the proceeds from this financing to support the continued clinical development of its lead product candidate, VAL-083, as a potential new treatment for refractory glioblastoma multiforme (GBM), and additional research into new indications including non-small cell lung cancer (NSCLC) and other solid tumors, and for general corporate purposes.
The securities described above have been offered pursuant to a registration statement (File No. 333-203357), which was declared effective by the United States Securities and Exchange Commission ("SEC") on July 15, 2015. Under the terms of the registration statement, the Company may issue up to 13,333,333 shares of common stock and 13,333,333 common stock purchase warrants for gross proceeds of up to $8 million. The registered offering will expire on July 31, 2015, unless extended to August 14, 2015 at the sole discretion of the Company.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there by any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus related to this offering may be obtained by clicking on the following link: http://ir.delmarpharma.com/all-sec-filings#document-14191-0001013762-15-000727
About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals, Inc. was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.
For further information, please visit http://delmarpharma.com/; or contact DelMar Pharmaceuticals Investor Relations: firstname.lastname@example.org / (604) 629-5989. Follow us on Twitter @DelMarPharma or Facebook.com/delmarpharma. Investor Relations Counsel: Amato & Partners LLC.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.
SOURCE DelMar Pharmaceuticals, Inc.